Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537]: committee papers
Table of Contents
01. NICE’s response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD – AbbVie (adalimumab)
02. Consultee comments on the ACD - Bristol Myers-Squibb (abatacept)
02. Consultee comments on the ACD - Hospira UK (infliximab biosimilar, Inflectra)
02. Consultee comments on the ACD - Napp Pharmaceuticals (infliximab biosimilar, Remsima)
02. Consultee comments on the ACD - Pfizer (etanercept)
02. Consultee comments on the ACD - Merck Sharp & Dohme Ltd (infliximab, golimumab)
02. Consultee comments on the ACD - Roche (tocilizumab)
02. Consultee comments on the ACD - UCB Pharma Ltd (certolizumab pegol)
02. Consultee comments on the ACD - Arthritis Care
02. Consultee comments on the ACD - National Rheumatoid Arthritis Society
02. Consultee comments on the ACD - British Society for Rheumatology
02. Consultee comments on the ACD - Royal College of Pathologists
03. Clinical expert comments on the ACD – Choy
04. Consultee and commentator comments on the Executable Model UCB
05. New evidence submitted at ACD stage Hospira
05. New evidence submitted at ACD stage Napp Pharmaceuticals
06. Additional analysis post consultation AG
![Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537]: committee papers](/proxy/?sourceUrl=http%3a%2f%2fwww.nice.org.uk%2fimages%2ficons%2fpdf.gif)
|
Rheumatoid arthritis - adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, abatacept and tocilizumab - review [ID537]: committee papers
03 September 2015 (4.79 Mb 47 sec) |
This page was last updated: 01 September 2015